Acute Kidney Injury Diagnosis and Staging

Introduction to KDIGO Criteria

The KDIGO criteria have been widely accepted as the standard for acute kidney injury (AKI) diagnosis and staging due to their harmonization and unification of previous definitions, and have been validated for both research and clinical practice, as endorsed by the Kidney International and American Journal of Kidney Diseases 1, 2

The KDIGO criteria have been independently validated in multiple studies, allowing for rigorous comparisons across populations and over time, with the Canadian Society of Nephrology noting that KDIGO harmonized prior definitions into a superior framework 2
The use of KDIGO criteria as part of computer decision-support systems can improve clinical outcomes, as demonstrated by large studies in different countries, with a strength of evidence supporting its effectiveness 3, 4
The KDIGO classification is preferred over RIFLE and AKIN, with the KDIGO nomenclature guidelines from 2020 explicitly stating that previous classifications should be avoided, as recommended by the Kidney International 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using the KDIGO criteria as the standard for AKI diagnosis and staging in both clinical practice and research, defining AKI as any of: creatinine increase ≥0.3 mg/dl within 48 hours, OR creatinine increase to ≥1.5 times baseline within 7 days, OR urine output <0.5 ml/kg/h for 6 hours, with a moderate strength of evidence supporting its use 1, 2
The KDIGO criteria have been endorsed by the Canadian Society of Nephrology, which explicitly states that RIFLE and AKIN definitions were validated but notes that KDIGO harmonized these prior definitions into a superior framework, with a high strength of evidence supporting its endorsement 2

The KDOQI US Commentary raised significant reservations about applying KDIGO criteria to guide clinical management of adult patients, noting potential for overdiagnosis and unnecessary nephrology consultations, with a low strength of evidence supporting its concerns 5, 6, 7
There are calls to revise KDIGO staging based on creatinine and urine output, with some suggesting that the case for revising the 2012 definition should be strong before changes are proposed, as discussed at the 2019 KDIGO controversies conference, with a moderate strength of evidence supporting the need for revision 3, 4

The RIFLE classification system defined AKI as a rise in creatinine of ≥50% from baseline value and/or a fall in the glomerular filtration rate (GFR) by ≥25%, and/or a decrease in urine output below 0.5 ml/kg/h for 6 hours or more, as proposed by the Acute Dialysis Quality Initiative workgroup 8
The Acute Kidney Injury Network (AKIN) published their AKI classification in 2007, which added a ≥0.3 mg/dl rise in creatinine within 48 hours to the definition of stage 1 AKI, and removed GFR criteria as markers of adult AKI 8
The Kidney Disease Improving Global Outcomes (KDIGO) guideline merged elements from both RIFLE and AKIN criteria, maintaining the 0.3 mg/dl increase within 48 hours or ≥50% increase within 7 days from AKIN, and modified criteria for stage 3 AKI to include rises in creatinine to ≥4.0 mg/dl 9

The AKIN criteria stipulated that adequate fluid resuscitation should have been undertaken and urinary obstruction excluded before applying the criteria, as recommended by the American Journal of Kidney Diseases 9
The KDIGO guideline maintained the 0.3 mg/dl increase within 48 hours or ≥50% increase within 7 days from AKIN, and modified criteria for stage 3 AKI to include rises in creatinine to ≥4.0 mg/dl, based on recommendations from the American Journal of Kidney Diseases 9

Even small increases in serum creatinine (≥0.3 mg/dl) are independently associated with approximately fourfold increase in hospital mortality, according to Kidney International 8
The classification systems have standardized the definition of AKI, allowing for better epidemiological comparisons across populations and over time, as well as standardization of entry criteria and endpoints in clinical trials, as stated by the American Journal of Kidney Diseases 10